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B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of 
leukemias. Normally, CLL is a disease of adults, but in most cases, it can occur in 
teenagers and occasionally in children (inherited). Most of the people are diagnosed 
without symptoms as the result of a routine blood test that returns a high white blood 
cell count. CLL is first suspected by the presence of lymphocytosis; however, it is 
increasing the number of adults with an increment of aberrant B cells populations before 
a lymphocytosis appears. 
In our study, we have developed two functional proteomics approaches for 
biomarker discovery useful in early diagnostic:  
i.-Determination of cell surface proteins by antibody arrays (antigens CDs). This 
simple methodology enables rapid and semi-quantitative immuno-phenotyping. By this 
approach, it is easy identify aberrant B-cells populations, all of them positive for: CD44, 
CD5, CD37, CD19, CD20, CD52, CD45RA, CD22, CD24, CD45,...). 
ii.-Beads based arrays: This methodology allows to determine, by flow 
cytometry, simultaneously hundreds of sera and/or intracellular proteins. Differences in 
protein expression profiles of aberrant B cells and normal B cells open a new hallmark 
in diagnostic and prognostic; among others ZAP-70, AKT1, JAK-STAT,MDM2,.... 
 
